Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Oklahoma Supreme Court Throws Out $465 Million Opioid Lawsuit Against Johnson & Johnson

11/09/2021 | 02:53pm EST


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
MT
01/13Divco West Real Estate Services, LLC acquired 143,000 square feet, 5000 Shoreline Court..
CI
01/12Johnson & Johnson's COVID-19 Vaccine Fact Sheet Updated to Include Risk of Rare Bleedin..
MT
01/12South African Institute To Study Effects Of Pfizer, BioNTech, Johnson & Johnson Booster..
MT
01/11US FDA Adds Risk of Rare Bleeding Disorder to Johnson & Johnson COVID-19 Jab's Fact She..
MT
01/11Mix and Match Covid-19 Vaccine Study to Take Place in Mozambique
AQ
01/10Johnson & Johnson Mulls Inorganic Opportunities
CI
01/10EU Agency To Meet With Vaccine Makers On Omicron Shot Trials; Approval Expected For Pfi..
MT
01/09Wisconsin Sen. Ron Johnson will run for re-election
AQ
01/07Georgia Enters $26 Billion Multi-State Opioid Litigation Settlement With Johnson & John..
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 306 M - -
Net income 2021 22 542 M - -
Net Debt 2021 596 M - -
P/E ratio 2021 19,9x
Yield 2021 2,47%
Capitalization 442 B 442 B -
EV / Sales 2021 4,69x
EV / Sales 2022 4,37x
Nbr of Employees 134 500
Free-Float -
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 167,84 $
Average target price 183,50 $
Spread / Average Target 9,33%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Alex Gorsky Executive Chairman
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-1.35%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317
NOVO NORDISK A/S-15.01%218 444